AlloHCT With PegINFa for Myelofibrosis
Part of paid clinical trials in Salt Lake City, Utah.
- Sponsor
- University of Utah
- Study ID
- NCT05535764
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Myelofibrosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pegylated interferon alpha2a — DRUGPegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.
Study Details
This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.
Key Dates
- Start date
- Aug 2, 2023
- Status verified
- Jun 2026
- Primary completion
- Aug 31, 2026
- Completion
- Mar 31, 2028
Study Design
- Enrollment
- 18 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment: All PatientsA 3+3 dose de-escalation design will be used to determine the recommended phase 2 dose,while ensuring the safety and tolerability of the treatment. In this trial, the dose determined to be the maximum tolerated dose will be the recommended phase 2 dose and will be utilized in the cohort expansion.
Primary Outcome Measure
Rate of dose-limiting toxicities (DLTs) during the DLT evaluation period [ Time Frame: Start of treatment to 86 days after treatment initiation ]
Central Contacts
- Rachel Kingsford801-585-0115
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Huntsman Cancer Institute at the University of Utah | Salt Lake City | Utah | 84112 | Sagar Patel, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Salt Lake City, UT
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisPHASE1/PHASE2 · Recruiting · Sumitomo Pharma America, Inc. · Birmingham, Alabama
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.PHASE1 · Recruiting · Newave Pharmaceutical Inc · Chicago, Illinois
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaPHASE2 · Recruiting · Karyopharm Therapeutics Inc · Duarte, California